$2500 | Single User
$5000 | Site License
$7500 | Enterprise License

Insulin Pens - Medical Devices Pipeline Assessment, 2016
[Lowest Price Guaranteed: $2,500]

Published by Global Data: 01 May 2016 | 26498 | In Stock
Related Topics: Medical , Medical Devices

Introduction

Insulin Pens - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, “Insulin Pens - Medical Devices Pipeline Assessment, 2016" provides an overview of Insulin Pens currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Insulin Pens pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Insulin Pens under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Insulin Pens and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to -

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Insulin Pens under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table of Contents
for Insulin Pens - Medical Devices Pipeline Assessment, 2016

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 5

    1.2 List of Figures 5

    2 Introduction 6

    2.1 Insulin Pens Overview 6

    3 Products under Development 7

    3.1 Insulin Pens - Pipeline Products by Stage of Development 7

    3.2 Insulin Pens - Pipeline Products by Segment 8

    3.3 Insulin Pens - Pipeline Products by Territory 9

    3.4 Insulin Pens - Pipeline Products by Regulatory Path 10

    3.5 Insulin Pens - Pipeline Products by Estimated Approval Date 11

    4 Insulin Pens - Pipeline Products under Development by Companies 12

    4.1 Insulin Pens Companies - Pipeline Products by Stage of Development 12

    4.2 Insulin Pens - Pipeline Products by Stage of Development 13

    5 Insulin Pens Companies and Product Overview 14

    5.1 Becton, Dickinson and Company Company Overview 14

    5.1.1 Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview 14

    5.2 Calibra Medical, Inc. Company Overview 16

    5.2.1 Calibra Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16

    5.3 Cambridge Consultants Limited Company Overview 17

    5.3.1 Cambridge Consultants Limited Pipeline Products & Ongoing Clinical Trials Overview 17

    5.4 Companion Medical, Inc. Company Overview 19

    5.4.1 Companion Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

    5.5 Emperra GmbH E-Health Technologies Company Overview 20

    5.5.1 Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview 20

    5.6 MedPro Safety Products, Inc. Company Overview 22

    5.6.1 MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22

    5.7 MicroPort Scientific Corporation Company Overview 23

    5.7.1 MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 23

    5.8 Sanofi Company Overview 25

    5.8.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 25

    6 Insulin Pens- Recent Developments 27

    6.1 Mar 23, 2016: B. Braun's growth trend continues 27

    6.2 Mar 10, 2016: Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer 28

    6.3 Mar 08, 2016: Antares Pharma Reports Fourth Quarter and Full Year 2015 Operating and Financial Results 28

    6.4 Mar 07, 2016: InsuLine Medical to Raise Funds in Financing Round 30

    6.5 Feb 09, 2016: Sanofi Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance 30

    6.6 Feb 04, 2016: Sanofi India Announces Results for the Quarter & Year Ended December 31, 2015 38

    6.7 Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter 38

    6.8 Jan 26, 2016: Antares Pharma Announces CEO Transition 39

    6.9 Jan 21, 2016: U.S. Food and Drug Administration Approves Humulin R U-500 KwikPen 40

    6.10 Jan 21, 2016: Singularity University and BD Announce Collaboration Dedicated to Address Global Healthcare Challenges 40

    6.11 Jan 21, 2016: Biocon Q3FY16 Net Profit Up 13% at Rs 103 Crore, EBITDA Increases 23% to Rs 209 Crore, Revenues at Rs 857 Crore, up by 10% 41

    6.12 Jan 11, 2016: Insulet Enters into Co-Development Agreement with Eli Lilly 44

    6.13 Jan 05, 2016: Ypsomed Enters into Distribution Agreement with Tonghua Dongbao Pharma 44

    6.14 Dec 04, 2015: Change in B. Braun Management Board 44

    6.15 Dec 01, 2015: Owen Mumford Launches New Touch Activated Lancet 44

    6.16 Nov 20, 2015: Sanofi India Announces Sale of Building in Andheri, Mumbai 45

    6.17 Nov 05, 2015: Antares Pharma Reports Third Quarter 2015 Operating and Financial Results 45

    6.18 Nov 04, 2015: BD Announces Results For 2015 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2016 Guidance 46

    6.19 Oct 20, 2015: Sanofi India - Outcome of Board Meeting 48

    6.20 Oct 20, 2015: Sanofi India Announces Q3 results & Limited Review Report for the quarter ended September 30, 2015 48

    6.21 Sep 22, 2015: Novo Nordisk and the Food and Drug Administration of the Islamic Republic of Iran sign memorandum of understanding to build manufacturing facility in Iran 48

    6.22 Sep 16, 2015: Sanofi's CSR Achievements Recognized In The Dow Jones Sustainability Indices 49

    6.23 Sep 15, 2015: Biocon Inaugurates World Class Devices Facility & Introduces Basalog One 49

    6.24 Sep 15, 2015: Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 50

    6.25 Sep 15, 2015: Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 50

    6.26 Sep 15, 2015: BD Named 2015 Outstanding Corporate Innovator Winner by Product Development and Management Association 50

    6.27 Sep 15, 2015: Biocon Inaugurates World Class Devices Facility 51

    6.28 Aug 24, 2015: Biocon Clarifies On FDA’s Inspection 51

    6.29 Aug 18, 2015: Lilly's Humalog 200 units/mL KwikPen Now Available in U.S. Pharmacies 51

    6.30 Aug 10, 2015: Antares Pharma Reports Second Quarter 2015 Operating and Financial Results 52

    6.31 Aug 06, 2015: BD Announces Results for 2015 Third Fiscal Quarter and Raises EPS Guidance for Fiscal 2015 53

    6.32 Jul 30, 2015: Sanofi delivers solid sales and business EPS(1) growth in Q2 2015 55

    6.33 Jul 23, 2015: Biocon's Earnings Surge in Q1 FY16; Revenue up by 15% at Rs. 857 Crore, Net Profit up by 23% at Rs. 126 Crore 62

    6.34 Jul 23, 2015: Appointment of Chief Financial Officer : Sanofi India 63

    6.35 Jul 21, 2015: Sanofi India Announces Q2 results 63

    6.36 Jul 15, 2015: Sanofi Announces New, Global Business Unit Structure To Drive Future Growth 64

    6.37 Jul 15, 2015: BD Opens Advance Diabetes Care Headquarters in Andover, Mass. 64

    6.38 Jul 14, 2015: Antares Pharma Appoints Peter J. Graham Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary 65

    6.39 Jul 13, 2015: BD Announces Sustainability Goals for 2020 65

    6.40 Jul 09, 2015: Gerresheimer substantially improves operating earnings in second quarter 66

    6.41 Jul 08, 2015: BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 67

    6.42 Jul 01, 2015: Haselmeier Group Announces the Extension and Reorganization of its Executive Board 67

    6.43 Jun 30, 2015: Ypsomed now supplies the YpsoPen in Poland 68

    6.44 Jun 24, 2015: EMPERRA's Bluetooth-enabled ESYSTA Smart Insulin Pen in the Last Stages of the CE Approval Process 68

    6.45 Jun 06, 2015: New Clinical Data Suggest Infusion Set with BD FlowSmart Technology May Improve Insulin Flow and Reduce Silent Occlusions 70

    6.46 Jun 02, 2015: BD Participates in White House Forum on Antibiotic Stewardship 71

    6.47 May 27, 2015: U.S. Food and Drug Administration Approves Humalog 200 units/mL KwikPen 71

    6.48 May 21, 2015: Haselmeier receives prestigious accolade for two of their products: The international GOOD DESIGN Award 2014 72

    6.49 May 20, 2015: Companion Medical Raises USD3.15 Million in Series B Financing 72

    6.50 May 18, 2015: Haselmeier Group Announces the Relocation of Haselmeier in the United States 73

    6.51 May 15, 2015: Sanofi Announces Departure Of Chief Strategy Officer 73

    6.52 May 13, 2015: DuBiotech Welcomes Germany’s B.Braun 73

    6.53 May 11, 2015: Antares Pharma Reports First Quarter 2015 Operating and Financial Results 74

    6.54 May 11, 2015: Antares Pharma Reports First Quarter 2015 Financial and Operating Results 75

    6.55 May 07, 2015: BD Announces Results For 2015 Second Fiscal Quarter 77

    6.56 May 07, 2015: Biocon-Mylan Programs Make Progress: PEG-G-CSF and Adalimumab enter Phase 3 clinical trials; Patient recruitment for one Insulin Glargine Phase 3 study completed 78

    7 Appendix 79

    7.1 Methodology 79

    7.2 About GlobalData 81

    7.3 Contact Us 82

    7.4 Disclaimer 82

List Of Tables
in Insulin Pens - Medical Devices Pipeline Assessment, 2016

1.1 List of Tables

Table 1: Insulin Pens - Pipeline Products by Stage of Development 7

Table 2: Insulin Pens - Pipeline Products by Segment 8

Table 3: Insulin Pens - Pipeline Products by Territory 9

Table 4: Insulin Pens - Pipeline Products by Regulatory Path 10

Table 5: Insulin Pens - Pipeline Products by Estimated Approval Date 11

Table 6: Insulin Pens Companies - Pipeline Products by Stage of Development 12

Table 7: Insulin Pens - Pipeline Products by Stage of Development 13

Table 8: Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview 14

Table 9: Next Generation Pen Needle II - Product Status 15

Table 10: Next Generation Pen Needle II - Product Description 15

Table 11: Calibra Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 16

Table 12: Pre-Filled Insulin Device - Product Status 16

Table 13: Pre-Filled Insulin Device - Product Description 16

Table 14: Cambridge Consultants Limited Pipeline Products & Ongoing Clinical Trials Overview 17

Table 15: KiCoPen - Product Status 18

Table 16: KiCoPen - Product Description 18

Table 17: Companion Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 19

Table 18: Insulin Pen - Product Status 19

Table 19: Insulin Pen - Product Description 19

Table 20: Emperra GmbH E-Health Technologies Pipeline Products & Ongoing Clinical Trials Overview 20

Table 21: Bluetooth-enabled ESYSTA Smart Insulin Pen - Product Status 21

Table 22: Bluetooth-enabled ESYSTA Smart Insulin Pen - Product Description 21

Table 23: MedPro Safety Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 22

Table 24: Insulin Guard Self-Injector Safety Needle - Product Status 22

Table 25: Insulin Guard Self-Injector Safety Needle - Product Description 22

Table 26: MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview 23

Table 27: La Fenice Pen - Product Status 24

Table 28: La Fenice Pen - Product Description 24

Table 29: Sanofi Pipeline Products & Ongoing Clinical Trials Overview 25

Table 30: Fix-Flex Device - Product Status 26

Table 31: Fix-Flex Device - Product Description 26

Table 32: Glossary 80

List Of Figures, Charts and Diagrams
in Insulin Pens - Medical Devices Pipeline Assessment, 2016

1.2 List of Figures

Figure 1: Insulin Pens - Pipeline Products by Stage of Development 7

Figure 2: Insulin Pens - Pipeline Products by Segment 8

Figure 3: Insulin Pens - Pipeline Products by Territory 9

Figure 4: Insulin Pens - Pipeline Products by Regulatory Path 10

Figure 5: Insulin Pens - Pipeline Products by Estimated Approval Date 11

Additional Details

Publisher

Global Data

Publisher Information

Reference

26498 | GDME0176EPD

Number of Pages

82

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Latin America Infusion Pump Market by Product (Volumetric, Syringe, Feeding, Insulin, PCA Pump), Application (Chemotherapy, Gastroenterology, Diabetes, Pain Management), Setting (Hospital, Ambulatory Centers), Accessories - Forecast to 2021
The Latin American infusion pumps and accessories market is estimated to reach USD 671.9 million by ...
20 Sep 2016 by MarketsandMarkets USD $5,650 More Info
Insulin Pumps - Medical Devices Pipeline Assessment, 2016
Insulin Pumps - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Devices sector ...
09 May 2016 by Global Data USD $2,500 More Info
Insulin Pens - Medical Devices Pipeline Assessment, 2016
Insulin Pens - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Devices sector r...
01 May 2016 by Global Data USD $2,500 More Info
Disposable Insulin Pumps - Medical Devices Pipeline Assessment, 2016
Disposable Insulin Pumps - Medical Devices Pipeline Assessment, 2016SummaryGlobalData's Medical Devi...
01 Apr 2016 by Global Data USD $2,500 More Info
Infusion Pump Market - by Product (Volumetric, Syringe, Feeding, Insulin, PCA Pump), by Application (Chemotherapy, Gastroenterology, Diabetes, Pain Management), by End User (Hospital, Home Care, Ambulatory Surgery Centers) - Global Forecast to 2020
The global infusion pumps and accessories market is expected to grow at a CAGR of 5.8% during the fo...
11 Jan 2016 by MarketsandMarkets USD $4,650 More Info
Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020
The global human insulin market is poised to reach ~USD 39.13 billion by 2020 growing at a CAGR of 8...
04 Jan 2016 by MarketsandMarkets USD $4,650 More Info
Physician Views: The return of inhaled insulin – a paradigm shift or hard sell?
Scope Sanofi is currently in the process of launching Afrezza in the US market. Afrezza is an inhale...
13 Feb 2015 by FirstWord Pharma USD $695 More Info
Physician Views: What opportunity for biosimilar basal insulin?
Scope Two weeks ago, Sanofi significantly downgraded internal revenue projections for Lantus, its lo...
12 Nov 2014 by FirstWord Pharma USD $695 More Info
Physician Views: As MannKind's Afrezza nears approval, what opportunity for an inhaled insulin?
Scope MannKind's confirmation that the FDA has extended the PDUFA date for its inhaled insulin Afrez...
10 Apr 2014 by FirstWord Pharma USD $695 More Info
Physician Views – Sanofi's no-go decision on lixisenatide monotherapy sharpens focus on GLP-1/insulin combination products – what are the expectations of GPs, endocrinologists based in the US, 5EU?
ScopeA key dynamic of the highly competitive diabetes market is the relatively limited differentiati...
01 Sep 2013 by FirstWord Pharma USD $695 More Info

This report is published by Global Data

Download Free Report Summary PDF

Insulin Pens - Medical Devices Pipeline Assessment, 2016 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...